Sharma, Rath et al. [17] stated that administration of Lactobacillus brevis CD2 lozenges in head and neck squamous cell carcinoma (HNSCC) patients enduring radiotherapy and concurrent cisplatin-based chemotherapy, reduced the incidence of severe OM (52% incidence in the intervention group versus 77% in the placebo group). Here, CD2 is linked to head and neck squamous cell carcinoma.